Mortality prediction in patients with severe septic shock: a pilot study using a target metabolomics approach

  • Sci Rep. 2016 Feb 5;6:20391. doi: 10.1038/srep20391.
Manuela Ferrario  1 Alice Cambiaghi  1 Laura Brunelli  2 Silvia Giordano  2 Pietro Caironi  3  4 Luca Guatteri  5 Ferdinando Raimondi  6 Luciano Gattinoni  3  4 Roberto Latini  2 Serge Masson  2 Giuseppe Ristagno  2 Roberta Pastorelli  2
Affiliations
  • 1. Politecnico di Milano, Milan, Italy.
  • 2. IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
  • 3. Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Fondazione IRCCS Ca' Granda -Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy.
  • 4. Dipartimento di Anestesia, Rianimazione, ed Emergenza Urgenza, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy.
  • 5. Azienda Ospedaliera di Desio, Desio, Italy.
  • 6. Azienda Ospedaliera Luigi Sacco, Milan, Italy.
Abstract

Septic shock remains a major problem in Intensive Care Unit, with high lethality and high-risk second lines treatments. In this preliminary retrospective investigation we examined plasma metabolome and clinical features in a subset of 20 patients with severe septic shock (SOFA score >8), enrolled in the multicenter Albumin Italian Outcome Sepsis study (ALBIOS, NCT00707122). Our purpose was to evaluate the changes of circulating metabolites in relation to mortality as a pilot study to be extended in a larger cohort. Patients were analyzed according to their 28-days and 90-days mortality. Metabolites were measured using a targeted mass spectrometry-based quantitative metabolomic approach that included acylcarnitines, aminoacids, biogenic amines, glycerophospholipids, sphingolipids, and sugars. Data-mining techniques were applied to evaluate the association of metabolites with mortality. Low unsaturated long-chain phosphatidylcholines and lysophosphatidylcholines species were associated with long-term survival (90-days) together with circulating kynurenine. Moreover, a decrease of these glycerophospholipids was associated to the event at 28-days and 90-days in combination with clinical variables such as cardiovascular SOFA score (28-day mortality model) or renal replacement therapy (90-day mortality model). Early changes in the plasma levels of both lipid species and kynurenine associated with mortality have potential implications for early intervention and discovering new target therapy.

Products